Cargando…

Dendritic Cell Vaccination in Non-Small Cell Lung Cancer: Remodeling the Tumor Immune Microenvironment

Non-small-cell lung cancer (NSCLC) remains one of the leading causes of death worldwide. While NSCLCs possess antigens that can potentially elicit T cell responses, defective tumor antigen presentation and T cell activation hinder host anti-tumor immune responses. The NSCLC tumor microenvironment (T...

Descripción completa

Detalles Bibliográficos
Autores principales: Abascal, Jensen, Oh, Michael S., Liclican, Elvira L., Dubinett, Steven M., Salehi-Rad, Ramin, Liu, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571973/
https://www.ncbi.nlm.nih.gov/pubmed/37830618
http://dx.doi.org/10.3390/cells12192404
_version_ 1785120127181651968
author Abascal, Jensen
Oh, Michael S.
Liclican, Elvira L.
Dubinett, Steven M.
Salehi-Rad, Ramin
Liu, Bin
author_facet Abascal, Jensen
Oh, Michael S.
Liclican, Elvira L.
Dubinett, Steven M.
Salehi-Rad, Ramin
Liu, Bin
author_sort Abascal, Jensen
collection PubMed
description Non-small-cell lung cancer (NSCLC) remains one of the leading causes of death worldwide. While NSCLCs possess antigens that can potentially elicit T cell responses, defective tumor antigen presentation and T cell activation hinder host anti-tumor immune responses. The NSCLC tumor microenvironment (TME) is composed of cellular and soluble mediators that can promote or combat tumor growth. The composition of the TME plays a critical role in promoting tumorigenesis and dictating anti-tumor immune responses to immunotherapy. Dendritic cells (DCs) are critical immune cells that activate anti-tumor T cell responses and sustain effector responses. DC vaccination is a promising cellular immunotherapy that has the potential to facilitate anti-tumor immune responses and transform the composition of the NSCLC TME via tumor antigen presentation and cell–cell communication. Here, we will review the features of the NSCLC TME with an emphasis on the immune cell phenotypes that directly interact with DCs. Additionally, we will summarize the major preclinical and clinical approaches for DC vaccine generation and examine how effective DC vaccination can transform the NSCLC TME toward a state of sustained anti-tumor immune signaling.
format Online
Article
Text
id pubmed-10571973
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105719732023-10-14 Dendritic Cell Vaccination in Non-Small Cell Lung Cancer: Remodeling the Tumor Immune Microenvironment Abascal, Jensen Oh, Michael S. Liclican, Elvira L. Dubinett, Steven M. Salehi-Rad, Ramin Liu, Bin Cells Review Non-small-cell lung cancer (NSCLC) remains one of the leading causes of death worldwide. While NSCLCs possess antigens that can potentially elicit T cell responses, defective tumor antigen presentation and T cell activation hinder host anti-tumor immune responses. The NSCLC tumor microenvironment (TME) is composed of cellular and soluble mediators that can promote or combat tumor growth. The composition of the TME plays a critical role in promoting tumorigenesis and dictating anti-tumor immune responses to immunotherapy. Dendritic cells (DCs) are critical immune cells that activate anti-tumor T cell responses and sustain effector responses. DC vaccination is a promising cellular immunotherapy that has the potential to facilitate anti-tumor immune responses and transform the composition of the NSCLC TME via tumor antigen presentation and cell–cell communication. Here, we will review the features of the NSCLC TME with an emphasis on the immune cell phenotypes that directly interact with DCs. Additionally, we will summarize the major preclinical and clinical approaches for DC vaccine generation and examine how effective DC vaccination can transform the NSCLC TME toward a state of sustained anti-tumor immune signaling. MDPI 2023-10-04 /pmc/articles/PMC10571973/ /pubmed/37830618 http://dx.doi.org/10.3390/cells12192404 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Abascal, Jensen
Oh, Michael S.
Liclican, Elvira L.
Dubinett, Steven M.
Salehi-Rad, Ramin
Liu, Bin
Dendritic Cell Vaccination in Non-Small Cell Lung Cancer: Remodeling the Tumor Immune Microenvironment
title Dendritic Cell Vaccination in Non-Small Cell Lung Cancer: Remodeling the Tumor Immune Microenvironment
title_full Dendritic Cell Vaccination in Non-Small Cell Lung Cancer: Remodeling the Tumor Immune Microenvironment
title_fullStr Dendritic Cell Vaccination in Non-Small Cell Lung Cancer: Remodeling the Tumor Immune Microenvironment
title_full_unstemmed Dendritic Cell Vaccination in Non-Small Cell Lung Cancer: Remodeling the Tumor Immune Microenvironment
title_short Dendritic Cell Vaccination in Non-Small Cell Lung Cancer: Remodeling the Tumor Immune Microenvironment
title_sort dendritic cell vaccination in non-small cell lung cancer: remodeling the tumor immune microenvironment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571973/
https://www.ncbi.nlm.nih.gov/pubmed/37830618
http://dx.doi.org/10.3390/cells12192404
work_keys_str_mv AT abascaljensen dendriticcellvaccinationinnonsmallcelllungcancerremodelingthetumorimmunemicroenvironment
AT ohmichaels dendriticcellvaccinationinnonsmallcelllungcancerremodelingthetumorimmunemicroenvironment
AT liclicanelviral dendriticcellvaccinationinnonsmallcelllungcancerremodelingthetumorimmunemicroenvironment
AT dubinettstevenm dendriticcellvaccinationinnonsmallcelllungcancerremodelingthetumorimmunemicroenvironment
AT salehiradramin dendriticcellvaccinationinnonsmallcelllungcancerremodelingthetumorimmunemicroenvironment
AT liubin dendriticcellvaccinationinnonsmallcelllungcancerremodelingthetumorimmunemicroenvironment